A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss
Part of paid clinical trials in Pelham, Alabama.
- Sponsor
- Eli Lilly and Company
- Study ID
- NCT04660643
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Tirzepatide — DRUGAdministered SC
- Placebo — OTHERAdministered SC
Study Details
This was a study of tirzepatide in participants with obesity or overweight. The main purpose was to learn more about how tirzepatide maintained body weight loss. The study had two phases: a lead-in phase in which all participants took tirzepatide and a treatment phase in which participants either continued tirzepatide or switched to placebo. The study lasted about 2 years (25 visits).
Key Dates
- Start date
- Mar 29, 2021
- Status verified
- May 2024
- Primary completion
- Apr 25, 2023
- Completion
- May 18, 2023
Study Design
- Enrollment
- 783 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Tirzepatide (lead-in)Participants received weekly doses of tirzepatide subcutaneously (SC) for 36 weeks, starting at 2.5 milligrams (mg) and increasing by 2.5 mg every 4 weeks, as tolerated, up to the maximum tolerated dose (MTD) of either 10 mg or 15 mg.
- Experimental: Tirzepatide MTDParticipants continued tirzepatide MTD (either 10 mg or 15 mg) for an additional 52 weeks.
- Placebo Comparator: PlaceboParticipants received weekly doses of placebo SC for 52 weeks.
Primary Outcome Measure
Percent Change From Randomization in Body Weight at Week 88 [ Time Frame: Randomization (Week 36), Week 88 ]
Locations (48)
Find similar trials in Pelham, AL
By condition
By specialty
Related Studies
- Diabetes and Heart Disease Risk in BlacksRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Physical and Behavioral Traits of Overweight and Obese AdultsRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular SystemRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Washington D.C., District of Columbia
- New Heart Imaging Techniques to Evaluate Possible Heart DiseaseRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland